Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

伊布替尼 套细胞淋巴瘤 慢性淋巴细胞白血病 淋巴瘤 脾边缘带淋巴瘤 边缘地带 癌症研究 医学 白血病 苯达莫司汀 威尼斯人 淋巴细胞增多症 内科学 免疫学 B细胞 抗体
作者
Hun Ju Lee,Michael Y. Choi,Tanya Siddiqi,Joanna Rhodes,William G. Wierda,Iris Isufi,Joseph M. Tuscano,Nicole Lamanna,Suki Subbiah,Jean L. Koff,Lori A. Leslie,Alec Goldenberg,Gina G. Chung,James B. Breitmeyer,S. Yazji,Michael Wang,Catriona Jamieson,Thomas J. Kipps
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 566-568 被引量:1
标识
DOI:10.1182/blood-2022-167153
摘要

Background: Zilovertamab (Zilo) is a humanized monoclonal antibody that inhibits the tumor promoting activity of the cancer stem cell antigen, ROR1, which is highly expressed by hematologic malignancies including MCL and CLL, and by many solid tumors but not by normal tissue specific stem cells. While pre-clinical studies showed that Zilo has additive or synergistic activity with targeted agents, such as the Bruton's tyrosine kinase inhibitor (BTKi) ibrutinib (Ibr), this is the first study showing clinical synergy. Methods: Patients (Pts) with relapsed or refractory (RR) MCL with ≥1 prior line of therapy (LOT) or treatment-naïve (TN) or RR CLL with ≥1 prior LOT were enrolled. In Part 1 (Dose Escalation in MCL, CLL), multiple doses were evaluated. As a result, Zilo 600 mg IV starting q2wks x3 then q4wks + Ibr 420mg (CLL/SLL) or 560 mg (MCL/MZL) daily dosing was selected as the recommended dosing regimen for use in Part 2 (Dose Expansion) and Part 3 (CLL only; pts randomized 2:1 to receive Zilo+Ibr vs. Ibr alone). The study opened to RR MZL pts with ≥1 prior anti-CD20 based therapy as of June 2022. Results: Sixty-seven pts (33 MCL and 34 CLL) were treated in Parts 1&2 and 28 pts (CLL) were treated in Part 3 of the study. In Parts 1 and 2, there were 27 RR MCL and 34 CLL (12 TN and 22 RR) efficacy evaluable pts. In Part 3, there were 23 efficacy-evaluable CLL pts randomized to receive either Zilo+Ibr (16) or Ibr (7). Safety in MCL and CLL: The most frequent (≥30%) treatment emergent adverse events (TEAEs), regardless of causality for all pts treated with Zilo+Ibr (N=85), were fatigue (42.4%), contusion (36.5%), and diarrhea (37.6%). The most frequent (≥5%) Grade ≥3 TEAEs, regardless of causality, were hypertension (10.6%), pneumonia (7.1%), neutropenia (5.9%), atrial fibrillation (5.9%), and fatigue (5.9%). In Parts 1 and 2, grade ≥3 hematologic laboratory abnormalities observed in pts with MCL and CLL, respectively, were neutrophils decrease (9.1% and 17.6%), platelets decrease (12.1% and 2.9%), and hemoglobin decrease (9.1% and 0%). Efficacy in MCL: The objective response rate (ORR) was 85.2% (40.7% CR, 44.4% PR) with a median duration of response (mDOR) of 34.1 months (mos) (95% CI:13.67, NE). The CR rate was 29.6%, 37% and 40.7% at 6, 12 and 26 mos, respectively. Median PFS (mPFS) was 35.9 mos (95% CI: 17.3, NE) with median follow-up (mf/u) of 15.1 mos and landmark PFS (LPFS) at 30 mos was ~70%. For 6 pts with P53 mutations, the ORR was 83.3% (1 CR, 4 PRs), mDOR was 13.84 mos (11.93, NE), mPFS was 17.3 (95% CI: 2.85, NE) and LPFS at 12 mos was >80%. In patients with Ki67≥30% (14), the ORR was 85.7% (5CRs, 7PRs) with mDOR NR (13.67, NE), for intermediate sMIPI (9) ORR was 88.9% (5 CRs, 3 PRs) with mDOR of 34.13 mos, and for high sMIPI (3) ORR was 66.7% (1 CR, 1PR) with mDOR NR (13.84, NE). Overall survival was not reached (NR; 95% CI: 18.9, NE) and landmark OS at 12 mos was ~90%. Efficacy in CLL: In Parts 1 and 2, the mPFS had not been reached for all pts with CLL with mf/u of 32.9 mos. The LPFS at 36 mos was 100% for pts with 1-2 prior LOT, ~70% for pts with >2 LOT. From pooled analysis of all Parts, the LPFS at 30 mos was 100% for the 9 pts with P53alterations.In Part 3, mPFS had not been reached in either group (Zilo+Ibr or Ibr) with mf/u of 24.1 mos Conclusions: In this study, Zilo+Ibr is well-tolerated with a safety profile that is very similar compared with Ibr alone. With respect to grade ≥3 neutropenia in RR MCL, the rate observed with Zilo+Ibr was 9.1%, which is lower than the 29% reported for Ibr alone in its Phase 3 study. The combination is very promising in pts with RR MCL (ORR 85.2%, CR 40.7%, mPFS 35.9 mos), compared with historical results for Ibr alone (ORR 66%, CR 20%, mPFS 12.8 mos; Rule 2017). For CLL pts with p53 alterations, overall efficacy with Zilo+Ibr is also very promising with LPFS at 30 mos of 100% that almost doubles historic Ibr monotherapy LPFS of ~55% (Byrd 2019). This encouraging exploratory study is ongoing, with the addition of MZL pts, and has provided the impetus for a Phase 3 registrational study evaluating Zilo+Ibr in MCL (ZILO-301).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
邓宸峰完成签到,获得积分10
刚刚
刚刚
夜未央完成签到 ,获得积分10
刚刚
1秒前
研友_VZG7GZ的应助被啊琴黎采纳,获得10
1秒前
隐形小兔子完成签到,获得积分10
1秒前
jiajia完成签到,获得积分10
1秒前
1秒前
huhuiya完成签到,获得积分10
2秒前
坚定的连虎完成签到,获得积分10
2秒前
3秒前
3秒前
清风完成签到,获得积分10
3秒前
fj完成签到,获得积分10
3秒前
fogsea发布了新的文献求助10
3秒前
goodbuhui完成签到,获得积分10
4秒前
4秒前
灶鲜森发布了新的文献求助10
4秒前
勤恳夏旋发布了新的文献求助10
4秒前
蓝精灵完成签到 ,获得积分10
5秒前
猫小咪发布了新的文献求助10
5秒前
天天快乐的应助被七月晴采纳,获得10
6秒前
huhuiya发布了新的文献求助10
6秒前
zxd发布了新的文献求助10
6秒前
动听的秋白完成签到 ,获得积分10
6秒前
迷魂不得完成签到,获得积分10
6秒前
水煮电吹风的应助被时途采纳,获得10
6秒前
秒文献是一种天赋完成签到 ,获得积分10
7秒前
2577完成签到 ,获得积分10
7秒前
王献杰完成签到,获得积分10
8秒前
杰杰小杰发布了新的文献求助10
8秒前
阿符家的骡完成签到,获得积分10
8秒前
ponysmile完成签到,获得积分10
8秒前
莫生发布了新的文献求助10
8秒前
白色大鸟完成签到,获得积分10
9秒前
安静又夏完成签到,获得积分10
9秒前
9秒前
qiyue完成签到 ,获得积分10
9秒前
山海完成签到,获得积分10
9秒前
hooray完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180135
求助须知:如何正确求助?哪些是违规求助? 9570290
关于积分的说明 21809391
捐赠科研通 7776237
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557465
邀请新用户注册赠送积分活动 2479039